RG
Repligen
RGEN·NASDAQWaltham MAFounded 19811,700 employees
Mid CapbiotechPublicOncology
Platform: Bioprocessing
Market Cap
$8B
All Drugs
4
Clinical Trials
4
Failed / Terminated
1
FDA Approved
0
Stock Price & Catalysts (RGEN)
Loading RGEN stock data...
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| RGE-6554 | RGE-6554 | Phase 1 | 1 | SMN2 | GISTEndometrial Ca | ||
| Sovazumab | RGE-8287 | Phase 1 | 1 | PSMA | NarcolepsySchizophrenia | ||
| Liralucimab | RGE-6157 | Phase 3 | 1 | APOC3 | TTR Amyloidosis | ||
| RGE-5524 | RGE-5524 | Phase 1 | 1 | RET | Atopic DermMelanoma |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (3)